MUCOSTA 100mg f.c.tab.

国家: 埃及

语言: 英文

来源: EDA (Egyptian Drug Authority)

下载 产品特点 (SPC)
01-03-2016

可用日期:

OTSUKA PHARMACEUTICAL-JAPAN

剂量:

100 mg

药物剂型:

coated tablet

每包单位数:

10 tablets

厂商:

OTSUKA EGYPT

授权日期:

2006-06-13

产品特点

                                Egypt Otsuka Pharmaceutical Co.,
1
BODY SYSTEM/
FREQUENCY
< 0.1%
*INCIDENCE
UNKNOWN
HYPER-
SENSITIVITY
(NOTE 1)
Rash, pruritus,
drug-eruption-like eczema,
other symptoms of
hypersensitivity
Urticaria
NEURO-
PSYCHIATRIC
Numbness, dizziness,
sleepiness
GASTRO-
INTESTINAL
Constipation, feeling of
abdomen enlarged, diarrhea,
nausea, vomiting, heartburn,
abdominal pain, belching, taste
abnormality, etc.
Thirst
Revised: March 2016 (2nd version )
- ANTI-GASTRITIS AND ANTI-GASTRIC ULCER DRUG –
MUCOSTA
®
TABLETS 100 MG
DESCRIPTION
1. COMPOSITION
BRAND NAME
ACTIVE INGREDIENT
INACTIVE INGREDIENTS
MUCOSTA
TABLETS
100
MG
Each tablet
contains 100
mg of
rebamipide
Microcrystalline cellulose,
Low substituted
Hydroxypropyl cellulose,
Hydroxypropyl cellulose,
Magnesium stearate,
Hydroxypropyl methyl
cellulose 2910, macrogol
6000, and Titanium oxide
2. PRODUCT DESCRIPTION
.Mucosta tablets 100 mg are round white film coated tablets
APPEARANCE
DIAMETER
(MM)
THICKNESS
(MM)
WEIGHT
(MG)
CODE
8.1
3.4
Approx
175
OG33
INDICATIONS
•
Gastric ulcers
•
Treatment of gastric mucosal lesions (erosion, bleeding,
redness, and edema) in the following conditions; acute
gastritis and acute exacerbation of chronic gastritis
DOSAGE AND ADMINISTRATION
•
Gastric ulcers: The usual adult dosage of rebamipide is
100 mg (1 tablet of
MUCOSTA TABLETS 100 MG
) taken
by the oral route three times daily, in the morning, in the
evening, and before bedtime.
•
Treatment of gastric mucosal lesions (erosion, bleeding,
redness, and edema) in the following conditions; acute
gastritis and acute exacerbation of chronic gastritis: The
usual adult dosage of rebamipide is 100 mg (1 tablet of
MUCOSTA TABLETS 100 MG
three times daily taken by
the oral route.
PRECAUTIONS
1. ADVERSE REACTIONS
Of 10,047 patients treated, adverse reactions, including
abnormal laboratory findings, were reported in 54 patients
(0.54%). Of 3,035 patients aged over 65 years, adverse
reactions were noted in 18 patients (0.59%). The nature
and incidence of adverse reactions showed no differenc
                                
                                阅读完整的文件
                                
                            

其他语言的文件

产品特点 产品特点 阿拉伯文 01-03-2016

搜索与此产品相关的警报